Your browser is no longer supported. Please, upgrade your browser.
Settings
KPTI Karyopharm Therapeutics Inc. daily Stock Chart
KPTI [NASD]
Karyopharm Therapeutics Inc.
Index- P/E- EPS (ttm)-3.44 Insider Own18.45% Shs Outstand62.30M Perf Week1.16%
Market Cap490.92M Forward P/E- EPS next Y-2.75 Insider Trans-12.43% Shs Float49.62M Perf Month31.55%
Income-206.10M PEG- EPS next Q-0.98 Inst Own95.30% Short Float17.66% Perf Quarter54.21%
Sales20.50M P/S23.95 EPS this Y-11.80% Inst Trans0.06% Short Ratio3.97 Perf Half Y-20.64%
Book/sh1.99 P/B3.96 EPS next Y26.90% ROA-74.60% Target Price19.75 Perf Year-57.03%
Cash/sh4.24 P/C1.86 EPS next 5Y- ROE-119.70% 52W Range3.92 - 21.71 Perf YTD-15.90%
Dividend- P/FCF- EPS past 5Y10.90% ROI-62.90% 52W High-63.70% Beta2.38
Dividend %- Quick Ratio6.20 Sales past 5Y139.20% Gross Margin- 52W Low101.02% ATR0.72
Employees332 Current Ratio6.20 Sales Q/Q-98.00% Oper. Margin- RSI (14)60.39 Volatility7.03% 11.45%
OptionableYes Debt/Eq0.86 EPS Q/Q-40.20% Profit Margin- Rel Volume0.53 Prev Close7.88
ShortableYes LT Debt/Eq0.86 EarningsAug 08 BMO Payout- Avg Volume2.21M Price7.88
Recom1.60 SMA2010.37% SMA5029.67% SMA200-1.95% Volume0 Change0.00%
Jul-05-19Reiterated Robert W. Baird Outperform $15 → $25
Jul-05-19Reiterated H.C. Wainwright Buy $29 → $32
Mar-01-19Downgrade JP Morgan Overweight → Neutral $21 → $7
Feb-28-19Reiterated BofA/Merrill Underperform $15 → $5
Feb-27-19Downgrade BofA/Merrill Neutral → Underperform $15 → $5
Jan-03-19Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18Initiated B. Riley FBR Buy $23
Nov-09-18Upgrade Wedbush Neutral → Outperform $19
May-24-18Downgrade Wedbush Outperform → Neutral $20 → $19
Apr-02-18Resumed Leerink Partners Outperform $19
Nov-15-17Resumed H.C. Wainwright Buy $23
Sep-15-17Initiated RBC Capital Mkts Outperform $14
Sep-08-16Reiterated H.C. Wainwright Buy $15 → $16
Aug-30-16Upgrade Jefferies Hold → Buy
Aug-18-16Initiated H.C. Wainwright Buy $15
Jun-28-16Initiated Robert W. Baird Outperform $16
May-27-16Initiated Raymond James Outperform $13
Mar-16-16Reiterated Wedbush Outperform $38 → $16
Jan-06-16Downgrade Jefferies Buy → Hold
Dec-22-15Initiated Canaccord Genuity Buy $20
Jul-09-19 07:35AM  Will Karyopharm Therapeutics Continue to Surge Higher? Zacks
Jul-05-19 04:16PM  Why Investors In This Biotech Stock Are Breathing A Sigh Of Relief Investor's Business Daily
02:12PM  Large Option Trader Dumps Karyopharm Puts Following Xpovio Approval Rally Benzinga
12:51PM  HC Wainwright Hikes Karyopharm Price Target On Accelerated Drug Approval Benzinga
10:14AM  Karyopharm Stock Is Soaring for a Second Day on a Key FDA Approval Barrons.com
08:55AM  The Daily Biotech Pulse: FDA Approves Karyopharm's Blood Cancer Treatment, Grifols' Immunodeficiency Drug; ESMO, ISTH Conferences In The Spotlight Benzinga
04:43AM  2 Attractive Biotechs With Key Study Outcomes on the Horizon TheStreet.com
Jul-04-19 09:45AM  Karyopharm Gets Accelerated FDA Approval for Myeloma Drug Zacks
Jul-03-19 04:26PM  Why Karyopharm Therapeutics Is Skyrocketing Motley Fool +36.03%
03:53PM  Why Symantec, NIO, and Karyopharm Therapeutics Jumped Today Motley Fool
03:51PM  UPDATE 2-Karyopharm Therapeutics prices blood cancer treatment after FDA approval Reuters
01:27PM  Karyopharm's stock soars to lead Nasdaq gainers before halt; XPOVIO gets FDA approval MarketWatch
01:13PM  CORRECTED-UPDATE 1-U.S. FDA approves Karyopharm Therapeutics' blood cancer drug Reuters
01:06PM  Karyopharm Announces FDA Approval of XPOVIO (selinexor) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma GlobeNewswire
01:02PM  Overriding safety concerns, FDA approves Karyopharm cancer drug American City Business Journals
12:57PM  U.S. FDA approves Karyopharm Therapeutics' blood cancer drug Reuters
Jun-28-19 04:37PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-26-19 08:56AM  Implied Volatility Surging for Karyopharm Therapeutics (KPTI) Stock Options Zacks
Jun-23-19 04:42PM  Heres What Hedge Funds Think About Karyopharm Therapeutics Inc (KPTI) Insider Monkey
Jun-20-19 11:48AM  Biotech companies dominate fastest-growing public companies list again American City Business Journals
Jun-14-19 07:00AM  Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting GlobeNewswire
Jun-07-19 11:25AM  Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Insiders Have Been Selling Simply Wall St.
Jun-03-19 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-28-19 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire -6.30%
May-21-19 10:51PM  Edited Transcript of KPTI earnings conference call or presentation 9-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 10:12PM  Karyopharm Therapeutics Inc. (KTPI) Q1 2019 Earnings Call Transcript Motley Fool
11:06AM  Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual Meeting GlobeNewswire
May-15-19 07:00AM  Karyopharms Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year Award GlobeNewswire
May-09-19 01:36PM  Heres What Hedge Funds Think About Karyopharm Therapeutics Inc (KPTI) Insider Monkey
08:25AM  Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:20AM  Karyopharm Therapeutics: 1Q Earnings Snapshot Associated Press
May-08-19 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
May-02-19 10:33AM  Earnings Preview: Karyopharm Therapeutics (KPTI) Q1 Earnings Expected to Decline Zacks
07:00AM  Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019 GlobeNewswire
May-01-19 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Apr-09-19 01:52PM  Karyopharm Therapeutics Inc. (NASDAQ:KPTI): Are Analysts Bullish? Simply Wall St. -6.06%
Apr-01-19 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -5.31%
Mar-18-19 04:31PM  Here's Why Karyopharm Therapeutics Climbed Today Motley Fool +12.74%
11:26AM  Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict Zacks
Mar-15-19 11:41AM  Why Karyopharm Therapeutics Stock Is Soaring Today Motley Fool +7.05%
07:39AM  The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 04:57PM  Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application PR Newswire
Mar-07-19 06:56PM  Edited Transcript of KPTI earnings conference call or presentation 28-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-04-19 08:46AM  Take a Poker Player's Approach to Playing Small Biotech Stocks TheStreet.com +7.42%
Mar-01-19 12:36PM  Steven Cohen Ups Bet on Karyopharm Therapeutics GuruFocus.com
Feb-28-19 04:51PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -6.14%
01:45PM  Karyopharm Therapeutics Inc (KPTI) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:00AM  Karyopharm Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update GlobeNewswire
Feb-27-19 11:31AM  Analysts Slash KaryoPharm Price Targets By Over 50% After Adcom Setback Benzinga -9.65%
08:13AM  The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings Benzinga
Feb-26-19 05:47PM  Karyopharm Announces Outcome of FDA Advisory Committee Meeting Reviewing Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma GlobeNewswire
12:31PM  Karyopharm Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies GlobeNewswire
07:56AM  The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote Benzinga
Feb-25-19 07:00AM  Karyopharm Strengthens Management Team with Appointment of Michael P. Mason as Chief Financial Officer GlobeNewswire
06:43AM  FDA panel says Karyopharm's cancer drug shows 'significant toxicity' American City Business Journals
Feb-22-19 04:10PM  Here's Why Karyopharm Therapeutics Is Getting Hammered Today Motley Fool -43.48%
03:15PM  Karyopharm Shares Nosedive On Tough FDA Briefing For Multiple Myeloma Drug Benzinga
Feb-21-19 07:35AM  Research Report Identifies Johnson & Johnson, Schlumberger, Karyopharm Therapeutics, WYNDHAM DESTINATIONS, INC, ASGN, and Suburban Propane Partners with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
07:00AM  Karyopharm to Report Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019 GlobeNewswire
Feb-07-19 07:00AM  Karyopharm Announces FDA Advisory Committee Meeting to Review Selinexor for the Treatment of Patients with Triple Class Refractory Multiple Myeloma Who Have Received At Least Three Prior Therapies GlobeNewswire
Feb-04-19 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +5.02%
Jan-11-19 03:51PM  Edited Transcript of KPTI earnings conference call or presentation 8-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Jan-09-19 09:45AM  Karyopharm Files MAA for Myeloma Candidate Selinexor in EU Zacks
Jan-08-19 12:20PM  Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma GlobeNewswire
Jan-02-19 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
09:25AM  How Financially Strong Is Karyopharm Therapeutics Inc. (NASDAQ:KPTI)? Simply Wall St.
07:00AM  Karyopharm to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-19-18 12:19AM  Karyopharm Therapeutics Inc (KPTI) Hedge Funds Are Snapping Up Insider Monkey
Dec-04-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-03-18 11:00AM  Karyopharm Reports Updated Selinexor Data from the Phase 2b STORM and Phase 1b/2 STOMP Studies in Relapsed/Refractory Multiple Myeloma at the American Society of Hematology 2018 Annual Meeting GlobeNewswire +5.38%
09:15AM  The 4 Healthcare Stocks To Watch On Monday ACCESSWIRE
Dec-01-18 12:00PM  Karyopharm Reports Positive Top-Line Phase 2b SADAL Data for Selinexor in Patients with Diffuse Large B-Cell Lymphoma at the American Society of Hematology 2018 Annual Meeting GlobeNewswire
Nov-13-18 08:10AM  Report: Developing Opportunities within Evelo Biosciences, ADMA Biologics, Karyopharm Therapeutics, Pingtan Marine Enterprise, Rosetta Stone, and Williams Companies Future Expectations, Projections Moving into 2018 GlobeNewswire
Nov-08-18 08:35AM  Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:34AM  Karyopharm Therapeutics: 3Q Earnings Snapshot Associated Press
07:00AM  Karyopharm Reports Third Quarter 2018 Financial Results and Highlights Recent Company Progress GlobeNewswire
Nov-07-18 08:00AM  Karyopharms Selinexor Receives Fast Track Designation from FDA for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma GlobeNewswire +6.24%
07:00AM  Karyopharm to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Nov-05-18 07:00AM  Karyopharm Therapeutics to Ring Nasdaq Closing Bell on November 6th GlobeNewswire
Nov-02-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-01-18 10:17AM  Karyopharm Announces Results of Clinical Studies Investigating Selinexor in Multiple Myeloma and Diffuse Large B-Cell Lymphoma to be Presented at the American Society of Hematology 2018 Annual Meeting GlobeNewswire +6.45%
07:00AM  Karyopharm to Report Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire
Oct-31-18 02:44PM  Is Karyopharm Therapeutics Inc (NASDAQ:KPTI) Potentially Underrated? Simply Wall St.
Oct-29-18 07:00AM  Karyopharm Therapeutics Announces Closing of Additional $22.5 Million of 3.00% Convertible Senior Notes Due 2025 Pursuant to Exercise in Full of Initial Purchasers Option GlobeNewswire
Oct-26-18 07:00AM  Karyopharm Therapeutics Announces Management Change GlobeNewswire
Oct-11-18 07:00AM  Karyopharm Therapeutics Announces Pricing of $150 Million of Convertible Senior Notes GlobeNewswire
Oct-09-18 04:01PM  Karyopharm Therapeutics Announces Proposed Private Offering of $150 Million of Convertible Senior Notes GlobeNewswire
Oct-05-18 05:43PM  U.S. Food and Drug Administration Accepts Karyopharms New Drug Application for Selinexor and Grants Priority Review GlobeNewswire
Oct-01-18 07:00AM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-25-18 07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-20-18 04:05PM  Selinexor Clinical Data to be Presented at the 21st Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-14-18 08:38AM  The Daily Biotech Pulse: FDA Nod For STAAR, Supernus Opens Wallet, Principia Biopharma To Debut Benzinga
Sep-13-18 07:20PM  Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting GlobeNewswire
Sep-04-18 04:05PM  Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
07:00AM  Karyopharm Appoints Carsten Thiel, Ph.D., to its Board of Directors GlobeNewswire
Aug-29-18 07:54AM  The Daily Biotech Pulse: Assertio Settles With Purdue, Emergent Biosolutions In M&A Mix, Novartis Eye Care Unit Recalls Stent Benzinga +9.32%
07:00AM  Karyopharm to Participate in Upcoming Investor Conferences GlobeNewswire
Aug-24-18 05:16PM  Karyopharm Therapeutics Ramps Up Hiring Ahead of Potential FDA Approval The Wall Street Journal
Aug-17-18 07:45AM  Report: Developing Opportunities within FORTERRA INC, Baytex Energy, MAG Silver, Bojangles', Ciner Resources LP, and Karyopharm Therapeutics Future Expectations, Projections Moving into 2018 GlobeNewswire
Aug-07-18 01:27PM  [$$] Papa John's and 3 Other Small-Cap Value Plays Barrons.com
Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme. The company is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-Hodgkin's lymphoma; KPT-335 that is in Phase IIb clinical trial for the treatment of pet dogs with cancer, as well as Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chione Ltd10% OwnerFeb 28Sale4.14149,624619,1146,000,000Mar 04 08:28 PM
Chione Ltd10% OwnerFeb 27Sale4.51558,2432,515,8346,149,624Feb 27 08:12 PM
Chione Ltd10% OwnerFeb 26Sale5.00123,400617,2106,707,867Feb 27 08:12 PM
Chione Ltd10% OwnerFeb 25Sale4.99800,0003,994,8806,831,267Feb 27 08:12 PM
Shacham SharonPresident & CSOJan 07Option Exercise0.0312,500413743,634Jan 09 04:37 PM
Kauffman MichaelChief Executive OfficerJan 07Option Exercise0.0312,500413743,634Jan 09 04:41 PM
Kauffman MichaelChief Executive OfficerJan 07Sale10.2312,500127,824731,134Jan 09 04:41 PM
Shacham SharonPresident & CSOJan 07Sale10.2312,500127,824731,134Jan 09 04:37 PM
Shacham SharonPresident & CSODec 07Option Exercise0.0312,500413726,010Dec 10 04:28 PM
Kauffman MichaelChief Executive OfficerDec 07Option Exercise0.0312,500413726,010Dec 10 04:29 PM
Kauffman MichaelChief Executive OfficerDec 07Sale10.1112,500126,423713,510Dec 10 04:29 PM
Shacham SharonPresident & CSODec 07Sale10.1112,500126,423713,510Dec 10 04:28 PM
Shacham SharonPresident & CSONov 26Option Exercise4.759,60045,619521,743Nov 27 04:20 PM
Kauffman MichaelChief Executive OfficerNov 26Option Exercise4.759,60045,619521,743Nov 27 04:17 PM
Shacham SharonPresident & CSONov 26Sale11.009,600105,600512,143Nov 27 04:20 PM
Kauffman MichaelChief Executive OfficerNov 26Sale11.009,600105,600512,143Nov 27 04:17 PM
Shacham SharonPresident & CSONov 19Option Exercise4.754001,901512,543Nov 21 08:03 AM
Kauffman MichaelChief Executive OfficerNov 19Option Exercise4.754001,901512,543Nov 21 08:00 AM
Shacham SharonPresident & CSONov 19Sale11.144004,455512,143Nov 21 08:03 AM
Kauffman MichaelChief Executive OfficerNov 19Sale11.144004,455512,143Nov 21 08:00 AM
Shacham SharonPresident & CSONov 07Option Exercise0.0312,500413726,010Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Option Exercise0.0312,500413726,010Nov 09 04:17 PM
Shacham SharonPresident & CSONov 07Sale11.6512,500145,593713,510Nov 09 04:16 PM
Kauffman MichaelChief Executive OfficerNov 07Sale11.6512,500145,593713,510Nov 09 04:17 PM
Shacham SharonPresident & CSOOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:09 PM
Kauffman MichaelChief Executive OfficerOct 18Option Exercise4.7510,00047,520522,143Oct 22 04:06 PM
Kauffman MichaelChief Executive OfficerOct 18Sale12.6310,000126,304512,143Oct 22 04:06 PM
Shacham SharonPresident & CSOOct 18Sale12.6310,000126,304512,143Oct 22 04:09 PM
Shacham SharonPresident & CSOOct 08Option Exercise0.0312,500413726,010Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Option Exercise0.0312,500413726,010Oct 09 08:05 AM
Shacham SharonPresident & CSOOct 08Sale15.7512,500196,832713,510Oct 09 08:00 AM
Kauffman MichaelChief Executive OfficerOct 08Sale15.7512,500196,832713,510Oct 09 08:05 AM
Kauffman MichaelChief Executive OfficerSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:23 PM
Shacham SharonPresident & CSOSep 18Option Exercise4.7510,00047,520522,143Sep 18 05:26 PM
Shacham SharonPresident & CSOSep 18Sale18.2610,000182,615512,143Sep 18 05:26 PM
Kauffman MichaelChief Executive OfficerSep 18Sale18.2610,000182,615512,143Sep 18 05:23 PM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 10Option Exercise8.4710,00084,65012,881Sep 11 06:08 PM
Primiano Christopher BrettEVP, CBO, GC & SecretarySep 10Sale18.9010,000189,0462,881Sep 11 06:08 PM
Shacham SharonPresident & CSOSep 07Option Exercise0.0312,500413726,010Sep 10 04:11 PM
Kauffman MichaelChief Executive OfficerSep 07Option Exercise0.0312,500413726,010Sep 10 04:13 PM
Kauffman MichaelChief Executive OfficerSep 07Sale19.3112,500241,384713,510Sep 10 04:13 PM
Shacham SharonPresident & CSOSep 07Sale19.3112,500241,384713,510Sep 10 04:11 PM
Chione Ltd10% OwnerSep 06Sale20.524,80098,4747,631,267Sep 07 06:27 PM
Chione Ltd10% OwnerSep 05Sale21.06160,0003,370,2567,636,067Sep 07 06:27 PM
Chione Ltd10% OwnerSep 04Sale20.6040,000824,0727,796,067Sep 04 06:59 PM
Chione Ltd10% OwnerAug 31Sale21.0511,468241,3967,836,067Sep 04 06:59 PM
Mirza Mansoor RazaDirectorAug 30Option Exercise1.922,5004,8102,236Sep 04 04:10 PM
Chione Ltd10% OwnerAug 30Sale21.00200,0004,199,9007,847,535Sep 04 06:59 PM
Mirza Mansoor RazaDirectorAug 30Sale21.002,50052,5000Sep 04 04:10 PM
Mirza Mansoor RazaDirectorAug 29Option Exercise1.492,5003,7132,500Aug 30 04:38 PM
Mirza Mansoor RazaDirectorAug 29Sale20.002,50050,0000Aug 30 04:38 PM
Chione Ltd10% OwnerAug 29Sale19.59200,0003,918,2808,047,535Aug 29 08:12 PM
Chione Ltd10% OwnerAug 27Sale18.5214,026259,7768,247,535Aug 29 08:12 PM
Shacham SharonPresident & CSOAug 20Option Exercise4.7510,00047,520522,143Aug 21 04:14 PM
Kauffman MichaelChief Executive OfficerAug 20Option Exercise4.7510,00047,520522,143Aug 21 04:11 PM
Shacham SharonPresident & CSOAug 20Sale17.4610,000174,568512,143Aug 21 04:14 PM
Kauffman MichaelChief Executive OfficerAug 20Sale17.4610,000174,568512,143Aug 21 04:11 PM
Chione Ltd10% OwnerAug 10Sale18.5070212,9878,261,561Aug 14 07:08 PM
Chione Ltd10% OwnerAug 09Sale18.5167,4741,248,7828,262,263Aug 09 08:24 PM
Chione Ltd10% OwnerAug 08Sale18.612,80052,0988,329,737Aug 09 08:24 PM
Shacham SharonPresident & CSOAug 07Option Exercise0.0312,500413726,010Aug 08 04:04 PM
Kauffman MichaelChief Executive OfficerAug 07Option Exercise0.0312,500413726,010Aug 08 04:08 PM
Chione Ltd10% OwnerAug 07Sale18.6010,602197,1978,332,537Aug 09 08:24 PM
Kauffman MichaelChief Executive OfficerAug 07Sale18.0412,500225,556713,510Aug 08 04:08 PM
Shacham SharonPresident & CSOAug 07Sale18.0412,500225,556713,510Aug 08 04:04 PM
Chione Ltd10% OwnerJul 25Sale18.5289516,5718,343,139Jul 25 07:55 PM
Chione Ltd10% OwnerJul 24Sale18.639,144170,3428,344,034Jul 25 07:55 PM
Chione Ltd10% OwnerJul 23Sale18.6620,000373,2228,353,178Jul 25 07:55 PM
Chione Ltd10% OwnerJul 20Sale19.2126,742513,8058,373,178Jul 23 05:00 PM
Chione Ltd10% OwnerJul 19Sale18.90100,0001,889,9408,399,920Jul 23 05:00 PM